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ABSTRACT
The incidence of cutaneous squamous cell carcinoma (cSCC) is rising. Whilst the 
majority are cured surgically, aggressive metastatic cSCC carry a poor prognosis. 
Inactivating mutations in transforming growth factor beta (TGF-β) receptors have 
been identified amongst genetic drivers of sporadic tumours and murine models of 
cSCC, suggesting a tumour suppressor function for TGF-β in normal skin. However, 
paradoxically, TGF-β acts as a tumour promoter in some murine model systems. 
Few studies have analysed the role of TGF-β/activin signalling in human normal 
skin, hyper-proliferative skin disorders and cSCC. Antibodies recognising phospho-
SMAD proteins which are activated during canonical TGF-β/activin signalling were 
validated for use in immunohistochemistry. A tissue microarray comprising FFPE 
lesional and perilesional tissue from human primary invasive cSCC (n=238), cSCC 
in-situ (n=2) and keratocanthoma (n=9) were analysed in comparison with tissues 
from normal human scalp (n=10). Phosphorylated SMAD2 and SMAD3 were detected 
in normal interfollicular epidermal keratinocytes and were also highly localised to 
inner root sheath, matrix cells and Keratin 15 positive cells. Lesional cSCC tissue had 
significantly reduced activated SMAD2/3 compared to perilesional tissue, consistent 
with a tumour suppressor role for SMAD2/3 activators in cSCC. Increased cSCC tumour 
thickness inversely correlated with the presence of phospho-SMADs in tumour tissue 
suggesting that a reduction in canonical TGF-β/activin signalling may be associated 
with disease progression.
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INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC) is the 
second most common skin cancer and one of the most 
common human cancers worldwide [1]. Whilst most 
lesions are cured surgically, a small subset of tumours 
are associated with a high-risk of soft tissue destruction, 
regional metastasis and poor prognosis [2]. Given its 
increasing incidence defining the molecular events 
that drive cSCC is an urgent research need. Mutational 
inactivation of TGF-β receptors in skin stem cells has 
recently been identified as a genetic driver in a subset of 
cSCC, suggesting an important role for TGF-β signalling 
in controlling skin homeostasis [3]. This observation is 
consistent with roles for TGF-β signalling in the regulation 
of many developmental and normal cellular responses [4] 
including tissue homeostasis, immune responses and cell 
differentiation [5]. However, when the TGF-β signalling 
pathway is disrupted it can also contribute to various 
pathological states ranging from immune disorders to 
fibrosis and cancer [5].
During cancer development, TGF-β signalling may 
act as either tumour suppressor or tumour promoter in a 
cell-type and context dependent fashion [6]. This duality 
of function is readily demonstrated in murine models of 
skin cancer. The constitutive over-expression of TGF-β 
ligand appears to protect supra-basal keratinocytes from 
TPA-induced epidermal hyperplasia, thereby impeding 
tumour formation via the regulation of keratinocyte 
proliferation and differentiation [7]. In contrast, in the 
same model systems and once tumours have progressed 
to invasive carcinoma, TGF-β functionally switches to 
promote invasion and metastasis [7, 8]. Equally discrepant 
are the few studies to examine mediators of TGF-β 
signalling in normal human skin and cSCC tissue, which 
report contradictory findings related to the relevance and 
level of expression of TGF-β ligands, TGF-β receptors and 
SMAD transcription factors [9–11]. It remains unclear, 
therefore, when TGF-β signalling might act to prevent or 
promote tumourigenesis in this disease.
TGF-β/activin signalling can be monitored by 
detection of carboxyl-terminal phosphorylated forms of 
TGF-β receptor-regulated intracellular signalling proteins 
(R-SMADs). Signalling is triggered when activated 
ligand binds to a constitutively active TGF-β type 2 
receptor (TGFBR2) at the cell membrane [12]. TGF-
β:TGFBR2 complex then recruits and activates the TGF-β 
type 1 receptor (TGFBR1) [13] which then activates 
the canonical SMAD transcription factors, SMAD2 and 
SMAD3, via C-terminal phosphorylation (PO4-) at serines 
465/467 and 433/435, respectively [14]. Activin signalling 
also induces C-terminal phosphorylation of SMAD2 and 
SMAD3 but via ACVR1B and ACVR2A/ACVR2B type 
1 and type 2 receptors, respectively. Once phosphorylated, 
PO4-SMAD2 and PO4-SMAD3 form a hetero-trimeric 
complex with the co-operative SMAD4, and translocate 
to the nucleus [15]. Within the nucleus the SMAD 
complexes, along with other transcriptional cofactors, 
regulate the transcriptional activation or repression of 
target genes [16].
In order to better understand the role of TGF-β/
activin signalling in human skin tumours (hereafter 
referred to as TGF-β signalling for simplicity), we 
characterise the expression of nuclear PO4-SMAD2 
and PO4-SMAD3 as markers of endogenous canonical 
TGF-β signalling activity within normal human skin and 
primary human cSCC samples. Overall, a reduction in 
endogenous PO4-SMAD2/3 levels were identified in cSCC 
tumours when compared to peri-lesional skin, supporting 
a tumour suppressor functional role for TGF-β/activin in 
squamous skin cancers. Further statistical analysis of PO4-
SMAD2/3 levels and their association with pathological 
features of cSCC demonstrate that increasing tumour 
depth (a known risk factor for nodal metastasis and poor 
prognosis) independently predicts a reduction in canonical 
TGF-β signalling activity. These findings suggest that a 
detectable reduction in PO4-SMAD2/3 levels within a 
primary tumour may be biologically associated with 
disease progression.
RESULTS
Validation of antibodies for IHC analysis
Antibodies specific for C-terminal phosphorylated 
forms of SMAD proteins (see supplementary methods) 
were validated initially for use in immunohistochemistry 
(IHC) on formalin-fixed paraffin embedded (FFPE) 
human tissue. The human cSCC cell line SCCIC4 [17] 
was treated in vitro with exogenous TGF-β1 ligand and/
or the Activin-Like Kinase 4 (ALK4)/TGFBR1(ALK5)/
ALK7 inhibitor, SB-431542 to induce or inhibit TGF-β 
signalling, respectively [18]. Western blot analysis of 
cell lysates confirmed active upregulation of C-terminal 
phosphorylation in SMAD2 and SMAD3 following 
treatment with TGF-β1 ligand (Figure 1A). PO4-SMAD2 
and PO4-SMAD3 expression was either undetectable 
or reduced to below basal levels in the presence of the 
TGFBR1 inhibitor SB-431542 (Figure 1A). Parallel 
cell samples were embedded in agarose gel pellets and 
processed for IHC staining. FFPE SB-431542 treated 
SCCIC4 cells were negative for nuclear PO4-SMAD2 
and PO4-SMAD3 staining. In contrast, strongly positive 
nuclear staining was detected in TGF-β1 treated cells 
(Figure 1B), validating both antibodies for IHC on FFPE 
human tissue.
Endogenous TGF-β signalling activity in normal 
human skin
The level and distribution of PO4-SMAD2 and PO4-
SMAD3 in sections from a panel of 10 normal human 
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scalp skin samples were then analysed by IHC within two 
skin regions, the inter-follicular epidermis (IFE) and the 
hair follicles (HF). Immuno-reactivity was examined and 
quantified by four independent scorers using the histoscore 
method [19] (Supplementary Methods and Supplementary 
Figure 1). Positive nuclear PO4-SMAD2 staining was 
consistently identified in both IFE (mean histoscore 118 
+/- 9.3 s.d.) and HF (mean histoscore 119.7 +/- 14.8 s.d) 
(Figure 2A-2B). Histoscores for PO4-SMAD3 IHC were 
lower in the IFE (mean histoscore 77.1 +/- 14.2 s.d) which 
is consistent with lower levels of total SMAD3 than total 
SMAD2 being detectable in isolated normal skin epidermis 
(Supplementary Figure 2). PO4-SMAD3 histoscores in 
adjacent HF (mean histoscore 126.8 +/- 23.8 s.d) (Figure 
2A-2B) were almost double the histoscores for IFE tissue.
High levels of both PO4-SMAD2 and PO4-SMAD3 
immuno-reactivity were also detected in the inner root 
sheath and hair follicle matrix (Supplementary Figure 3A-
3B). The matrix is particularly rich in highly proliferative 
matrix transit amplifying (MTA) cells during anagen, 
which are active intermediates of quiescent hair follicle 
bulge (HFB) stem cells [20]. We tested whether the HFB 
stem cells may represent a site of active endogenous 
TGF-β signalling. Human HFB stem cells are known to 
express KERATIN 15 (K15) [21] and richly populate the 
lower portion of the hair follicle during late catagen and 
telogen [22]. Serial sections of specimens, stained for 
both K15 and phosphorylated SMAD proteins (Figure 3), 
were screened specifically for late catagen and telogen 
hair follicles which appeared strongly positive for K15 
Figure 1: Validation of PO4-SMAD2 (Ser 465/467) and PO4-SMAD3 (Ser 433/435) antibodies for immunohistochem-
istry. SCCIC4 cells were pre-treated with 10μM TGFBR1 (ALK5) kinase inhibitor SB-431542 or DMSO vehicle control followed by 
addition of either 1ng/mL TGF-β1 or vehicle control (4mM HCl) for 1 hour as indicated. (A) Cell lysates were analysed by SDS-PAGE 
and western blotting using PO4-SMAD2, SMAD2, PO4-SMAD3 and SMAD3 specific antibodies as indicated. (B) Parallel cell samples 
treated with either TGF-β1 (positive samples) or SB-431542 (negative samples) as described above were pelleted into agarose and em-
bedded into paraffin wax for IHC. Representative digital images (x20 magnification, Aperio Imagescope) are shown. Scale bars = 50μM.
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immuno-reactivity. K15 expression consistently co-
localised with PO4-SMAD3 expression in HF at these 
stages (Figure 3).
Further sites of weak endogenous TGF-β signalling 
within the dermis included blood vessel walls and 
adjacent clusters of eccrine glands (Supplementary Figure 
3). These findings were confirmed by the site-specific 
nature of the staining and co-localisation between PO4-
SMAD expression and the endothelial cell marker CD31 
(Supplementary Figure 4A), indicating that endogenous 
TGF-β signalling may also be active in skin blood 
vessel walls. There was no correlation between PO4-
Figure 2: Endogenous TGF-β signalling in the interfollicular epidermis and hair follicle. (A) Representative IHC images of 
normal human scalp skin stained with anti-PO4-SMAD antibodies as indicated. IFE = Interfollicular epidermis. HF = Transverse sections 
through hair follicles within dermis. (B) Box and whisker plots comparing IFE and HF histoscores for normal human scalp skin samples 
(n=10) stained with indicated antibodies. ***= p<0.001 (Student t-test). Scale bars = 200μm.
Figure 3: Endogenous TGF-β signalling in Keratin 15 positive hair follicle bulge stem cells. Representative images of IHC 
of normal human scalp skin cut in serial section and stained with human bulge stem cell marker Keratin 15 (K15) and PO4-SMAD3, as 
indicated. Enlarged sections of Keratin 15 (i) and PO4-SMAD3 (ii) stained hair bulge are shown for comparison. Magnification and scale 
bars as marked.
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SMAD expression and the activated fibroblast marker, 
α-smooth muscle actin (α-SMA) (Supplementary Figure 
4B). This data indicates that in normal human epidermis, 
endogenous canonical TGF-β signalling exists at two sites, 
the IFE and the HF. Within the HF, high level activated 
SMAD expression appears to be present within the cellular 
compartments of the inner root sheath and the hair follicle 
matrix during anagen and K15 positive cells including the 
HFB stem cells during telogen stage of the hair follicle 
cycle.
PO4-SMAD2 and PO4-SMAD3 levels are reduced 
in invasive tumours compared to perilesional 
tissue
Next, a tissue microarray (TMA) of 249 primary 
squamo-proliferative lesions was examined. Of the 
249 samples, 230 primary cutaneous lesions were 
represented by more than one informative tissue core 
and so were included in the final histoscore analysis. 
Of the 230 lesions scored, 97.8% were primary cSCC 
(n=225) and 2.2% were KA (n=5). 77% of the lesions 
were excised from sun-exposed sites of the head and 
neck (177/230), 73.9% from male patients (170/230) 
and 63% from patients over 80 years old (145/230) 
(Table 1). The TMA was immuno-stained for PO4-
SMAD2 and PO4-SMAD3. Overall, a significant 
reduction in active nuclear PO4-SMAD2 and PO4-
SMAD3 staining was detected in invasive tumours when 
compared to site matched perilesional tissue (Figure 4). 
This finding indicates that impaired canonical TGF-β 
signalling activity represents a common feature of 
human primary invasive cSCC.
Clinical and pathological variables pertinent to 
cSCC tumour staging [23] were then examined for 
association with PO4-SMAD2 or PO4-SMAD3 histoscores 
(Table 1 and Supplementary Figures 5-6). Statistical 
analysis of variance (ANOVA; significant values p=< 
0.05) revealed no significant differences in mean PO4-
SMAD2 or PO4-SMAD3 histoscores analysed by patient 
sex, patient age, tumour pathological type (Table 1), 
tumour grade (Table 1 and Supplementary Figure 6A), 
tumour site (Table 1 and Supplementary Figure 5), the 
presence of peri-neural invasion (PNI) (Table 1 and 
Supplementary Figure 6B) or Clark level of invasion 
(Table 1 and Supplementary Figure 6C).
There was a significant reduction in mean PO4-
SMAD2 histoscores seen in larger diameter tumours 
(≥20mm versus <20mm) (Table 1 and Figure 5B, ANOVA; 
p=0.013) and a significant reduction in mean PO4-SMAD3 
histoscores seen in tumours invading beyond subcutaneous 
fat (Table 1 and Figure 5C, ANOVA; p=0.002). There 
were also significant reductions in mean PO4-SMAD2 and 
PO4-SMAD3 histoscores detected in thick tumours (≥4mm 
versus <4mm) (Table 1 and Figure 5A, ANOVA; p=0.01 
and p=0.006, respectively).
Reduced PO4-SMAD2 and PO4-SMAD3 levels 
correlate with large and thick invasive tumours
To investigate in more detail the potential 
association between PO4-SMAD histoscores and high-risk 
cSCC (defined as Breslow tumour depth ≥4mm, tumour 
diameter ≥20mm and invasion beyond subcutaneous fat), 
the data was re-analysed for significant correlations using 
Spearmann’s rank correlation co-efficient (C.C) (Table 2). 
High-risk tumour depths (≥4mm) demonstrated a highly 
significant negative dependence on both PO4-SMAD2 
(Table 2, C.C -0.214; p=0.001) and PO4-SMAD3 (Table 
2, C.C -0.200; p=0.002) (Supplementary Figures 7A and 
8) histoscores, suggesting a correlation between thicker 
tumours and lower SMAD2/3 phosphorylation. A subtle 
but significant negative dependence was also detected 
between higher maximum diameter tumours and PO4-
SMAD2 histoscores (Table 2, C.C -0.167; p=0.011, 
Supplementary Figure 7B). Consolidating these findings, 
lower levels of PO4-SMAD3 correlated with tumour 
invasion beyond the depth of subcutaneous fat (Table 2, 
C.C -0.187; p=0.005, Supplementary Figure 7C).
Higher tumour depth independently predicts 
lower endogenous TGF-β signalling activity
Next, a binary logistic regression analysis was 
performed, using the binary outcome PO4-SMAD2/PO4-
SMAD3 “off” (negative) (=1) and PO4-SMAD2/PO4-
SMAD3 “on” (positive) (=0) as the dependent variable 
(Table 3). The cut-off used for detecting PO4-SMAD2/
PO4-SMAD3 “off” was determined as a tumour histoscore 
of less than the 25th percentile of the mean in both PO4-
SMAD2 and PO4-SMAD3 staining. This analysis 
identified tumour depth as the only significant independent 
predictor of low PO4-SMAD expression (Table 3, Wald 
(Chi-squared) = 7.447; p = 0.006; Exp(B) = 1.127, 95% 
C.I 1.034-1.227), indicating that for each unit increase in 
tumour depth (mm), the odds of a tumour expressing a 
histoscore (for both PO4-SMAD2 and PO4-SMAD3) at 
levels below the 25th percentile of the mean increased 
by 12.7% (Table 3, (1.127*100)-100) – with a 95% C.I 
of 3.4%–22.7%). This analysis further strengthens the 
hypothesis that TGF-β signalling is likely to be acting 
primarily as a tumour suppressor in human primary cSCC 
and that impairment in canonical TGF-β signalling may be 
advantageous for tumour cell growth and invasion.
DISCUSSION
Detecting endogenous TGF-β activity in normal 
human skin
TGF-β plays vital homeostatic roles in normal 
skin and during skin injury repair, but some data from 
models of skin carcinogenesis are contradictory. The 
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Figure 4: Active endogenous TGF-β signalling is significantly reduced in invasive cSCC compared to perilesional 
tissue. (A) Representative images of tumour cores from TMA at 10-fold magnification, demonstrating varying degrees of histoscores 
from low (<50) to high (100-150) for PO4-SMAD2 and PO4-SMAD3 immunostaining as labelled. Tumour-Stroma heterogeneity labelled 
by arrow. (B) Graphical representative of mean histoscores for perilesional tissue (green) and tumour (red) across the whole TMA for PO4-
SMAD2 and PO4-SMAD3 immunostaining as labelled. 
*** p=<0.001 (Wilcoxon matched pairs test). Scale bar = 200μm.
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ligand appears to be consistently expressed throughout 
normal human epidermis [9, 11, 24] and its constitutive 
over-expression protects murine supra-basal keratinocytes 
from DMBA/TPA-induced epidermal hyperplasia [7, 25]. 
This protection appears to coincide with the induction of 
TGF-β’s obligate type 2 receptor (TGFBR2), indicating 
a vital role for TGF-β signalling in skin homeostasis. 
TGFBR2 is also strongly expressed in normal human IFE 
[9, 11]. However, expression of active TGF-β in the basal 
layer is also associated with inflammation and hyper-
proliferation [26].
Investigating the role of TGF-β superfamily ligands 
in skin homeostasis and disease has been problematic 
because of a lack of suitable reagents. Some researchers 
have relied on the detection of the TGF-β latency-
associated peptide, produced as part of the TGF-β 
latent precursor, as a surrogate marker of TGF-β ligand 
expression in tissues [7]. Since, in this form, TGF-β ligand 
is an inactive precursor protein, the biological relevance of 
IHC detection of ligand, associated peptides or receptor 
levels as tumour markers of endogenous signalling 
activity is debatable [27]. The formation of ligand-receptor 
complex is known to drive rapid depletion of receptors 
from the cell surface, which rate-limits the activation of 
down-stream TGF-β signalling [28]. Thus, in this study, 
neither the expression of TGF-β superfamily ligands or 
Table 1: Mean tumour PO4-SMAD histoscores for patient and tumour variables with analysis of 
variance
PO4-SMAD2 Tumour 
HISTOSCORES
PO4-SMAD3 Tumour 
HISTOSCORES
Variable Category Number Percent Mean S.D Sig. (ANOVA) Mean S.D Sig. (ANOVA)
Sex Male 170 73.9 89.06 24.36 57.73 23.14
Female 60 26.1 86.58 23.48 0.497 60.88 25.38 0.377
Site High-risk H&N 66 28.7 90.33 21.92 61.83 22.98
Low-risk H&N 111 48.3 86.95 24.39 56.72 23.71
Torso 5 2.2 72.29 23.99 44.67 24.08
Upper limb 38 16.5 92.05 26.94 59.79 25.53
Lower limb 9 3.9 94.92 21.69 62.84 19.79
Perineal 1 0.4 109.13 - 0.442 29.14 - 0.645
Grade < Poorly Diff 152 66.1 88.69 23.75 59.34 23.74
≥ Poorly Diff 78 33.9 87.88 24.94 0.81 57.01 23.75 0.481
Tumour 
Depth 
<4mm 115 50 92.50 24.64 62.83 22.77
≥4mm 115 50 84.33 22.96 0.01 54.28 23.99 0.006
Clark Level <IV 21 9.1 85.82 25.54 57.11 23.42
≥IV 209 90.9 88.68 24.01 0.605 58.69 23.8 0.771
Perineural 
Invasion
Absent 214 93 88.38 24.48 58.76 23.95
Present 16 7 88.98 18.94 0.922 55.79 21.03 0.631
Maximum 
Diameter
<20mm 168 73 90.81 23.36 59.97 23.58
≥20mm 62 27 81.92 25.09 0.013 54.7 23.88 0.135
Depth of 
Invasion
Up to 
subcutaneous fat
205 89.1 89.01 24.29 60.2 23.2
Beyond 
subcutaneous fat
25 10.9 83.5 22.41 0.282 45 24.07 0.002
 S.D = Standard Deviation, H&N = Sun-exposed head and neck, Clark Level IV = Invasion into the reticular dermis, 
ANOVA = One-way analysis of variance (significant p-value = <0.05).
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TGFBR2 were assessed because commercially available 
antibodies could not be validated for IHC on FFPE tissue 
to the same rigorous validation standards that we achieved 
for the anti- PO4-SMAD2 and PO4-SMAD3 antibodies. 
Nuclear PO4-SMAD2 expression was consistently 
observed within the human epidermis in this study and 
in others [9, 11, 29]. C-terminal phosphorylation of the 
R-SMAD’s is known to be sufficient for their nuclear 
accumulation and transcriptional activity [4]. As such, 
levels of phosphorylated R-SMAD’s can be correlated 
directly with TGF-β signal strength and transcriptional 
responses [30]. The selection of nuclear PO4-SMAD2/3 
expression was therefore considered appropriate as a direct 
marker of endogenous TGF-β signalling activity in human 
skin. At present though, we cannot formally identify 
which ligand has potential tumour suppressor function 
since other TGF-β superfamily members can also activate 
canonical PO4-SMAD2 and 3 via their own distinct serine 
threonine receptor kinase complexes including Activin, 
Nodal, and GDF-8 (myostatin) [31]. Activins are of 
particular interest, as they appear to share many of the 
regulatory characteristics of TGF-β in keratinocytes [32]. 
Figure 5: TMA histoscores identify a significant association between mean nuclear R-Smad expression and cSCC 
tumour depth, diameter and pathological depth of invasion. (A) Nuclear PO4-SMAD2 and PO4-SMAD3 activity by tumour 
depth, defined as <4mm and ≥4mm. (B) Nuclear PO4-SMAD2 and PO4-SMAD3 activity by maximum tumour diameter, defined as <20mm 
or ≥20mm. (C) Nuclear PO4-SMAD2 and PO4-SMAD3 activity by pathological depth of invasion. Grouped as invasion up to subcutaneous 
fat and invasion beyond subcutaneous fat. Analysis of Variance (ANOVA) Sig * p = <0.05, ** p = <0.01.
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Activin ligands are expressed mainly in the dermis, but 
their obligatory type 1 receptor (ACVR1B) is expressed in 
the epidermis, indicating that they could act in a paracrine 
fashion to regulate keratinocyte proliferation [33]. Co-
incidentally, Activin-A preferentially induces PO4-SMAD3 
expression in HaCaT human keratinocyte cells [34], thus 
other TGF-β superfamily members may also contribute to 
SMAD activation in human skin.
In keeping with TGF-β-mediated regulation of 
keratinocyte proliferation and differentiation, the level 
of nuclear PO4-SMAD2 expression was consistently 
high within the IFE, but, IFE PO4-SMAD3 histoscores 
were significantly lower overall. This apparent 
discrepancy could reflect a differential expression 
of total SMAD2 and SMAD3 proteins within the 
IFE. We could not assess total protein levels of non-
phosphorylated SMADs in FFPE sections as, again, the 
specificity of these antibodies could not be confirmed 
and there is a paucity of published data on total SMAD2 
or SMAD3 protein expression in normal human skin 
samples. A single study described expression of total 
SMAD2 and SMAD3 in the upper epidermal layers and 
hair follicles, but reported no obvious differences in 
levels [35]. However, our analysis of isolated epidermis 
from four normal skin donors, suggests that the levels 
of total detectable SMAD3 are lower than SMAD2 
which could account for the differential detection of 
phosphorylated SMAD proteins seen in this study. It is 
also possible that there is differential activation (PO4-
) of SMAD proteins within the epidermis but little is 
known about the potential biological mechanisms, 
or the affects, of any selective activation of SMAD2 
versus SMAD3 [36].
Immunostaining of human HF’s suggests that both 
SMAD2- and SMAD3-dependent TGF-β signalling 
are active in these specialised structures. Interestingly, 
this active signalling was detected at seemingly 
dichotomous points in the hair follicle cycle, localised 
to the proliferative MTA cells of anagen (growth phase) 
follicles, but also the Keratin 15 positive HFB stem cells 
of telogen (resting phase) follicles. Endogenous TGF-β1 
is known to suppress proliferation and induce apoptosis of 
MTA cells of the hair follicle bulb, driving the transition 
from anagen to catagen phases of the hair follicle cycle 
[37, 38]. This transition is characterised by a decline in 
proliferation and the differentiation of MTA cells in the 
hair follicle bulb. The MTA cells appeared rich in PO4-
SMAD2 and PO4-SMAD3 expression in this study, 
suggesting that endogenous SMAD-dependent TGF-β1-
driven signalling may be an integral regulator of human 
MTA cells. The expression of phosphorylated R-SMADs 
was also consistently localised to the HFB stem cells 
during telogen, consistent with recent murine studies [39]. 
This expression appears to be driven by the secretion of 
TGF-β2 ligand from adjacent DP cells, which in turn 
negatively regulates inhibitory BMP signalling, resulting 
in the activation of telogen HFB stem cells which drive 
hair follicle regeneration and a transition from telogen 
to anagen [39]. Our data are consistent with similar 
regulatory functions of TGF-β in human hair follicles.
TGF-β signalling in human cSCC
High-throughput genomic analyses of sporadic 
human invasive cSCC have demonstrated the presence 
of frequent mutations in TGF-β receptors [3, 40, 41], 
Table 2: Statistical correlations between cSCC perilesional and tumour TGF-β activity and selected “High-Risk” 
cSCC pathological variables
PO4-SMAD2 PO4-SMAD3 
Spearman's PO4-SMAD2 C.C .366***
Sig. (2-tailed) . .000
PO4-SMAD3 C.C .366***
Sig. (2-tailed) .000 .
Depth >4mm C.C -.214** -.200**
Sig. (2-tailed) .001 .002
Diameter >20mm C.C -.167* -.115
Sig. (2-tailed) .011 .081
Beyond 
subcutaneous fat
C.C -.101 -.187**
Sig. (2-tailed) .125 .005
C.C = Correlation co-efficient, Sig. = Significance, N = Number, S/C = Subcutaneous. 
***Correlation is significant at p = <0.001 level (2-tailed). **Correlation is significant at p = < 0.01 level (2-tailed). 
*Correlation is significant at p = < 0.05 level (2-tailed).
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indicating that TGF-β signalling is likely to act as a key 
tumour suppressor, and that mutational inactivation of this 
pathway may be a key driving event in tumour formation 
[3]. This proposed role is supported by evidence from 
three human “models” of squamous skin tumours: a 
clear genotype-phenotype correlation between germline 
inactivating TGFBR1 mutations and families suffering 
from multiple self-healing squamous epithelioma (MSSE) 
[42], the presence of TGFBR1 mutations in sorafenib-
induced skin tumours [43] and clinical cancer trial data 
reporting spontaneous cSCC arising as a side-effect of 
systemic treatment with the pan-TGF-β ligand antibody, 
GC1008 [44].
Our current study, reporting an analysis of possibly 
the largest published TMA of primary human cSCC 
to date, supports the idea that loss of canonical TGFβ 
pathway signalling is associated with cSCC disease 
progression. Overall, despite some contradictory evidence, 
data from alternative IHC studies in human disease appear 
consistent with our finding of a trend towards attenuation 
of TGF-β signalling [9-11, 35]. Whilst Harradine 
et al reported elevated SMAD activation, their analysis 
discussed only a direct comparison of mediators of 
TGF-β signalling between tumours from organ transplant 
recipients and sporadic tumours from the non-transplant 
recipient population [11]. The same data, when comparing 
tumour progression from normal to invasive carcinoma, 
irrespective of tumour host, suggests an overall reduction 
in PO4-SMAD2 staining intensities [11]. This current 
study provides the added assurances that we compare 
lesional with peri-lesional uninvolved tissue and that the 
antibodies used were carefully validated prior to use.
The histoscore scoring method averages variation in 
immunostaining across tissue cores, therefore, the extent 
of possible heterogeneity of TGF-β signalling throughout 
the tumour tissue was not directly addressed in this study. 
A more in-depth examination of cell or site-specific 
TGF-β signalling activity in cSCC (e.g active signalling 
localised to the leading invasive edges of tumour) might 
reveal further clues as to where the likely biological roles 
for active TGF-β signalling lie.
No previous study has examined correlations 
between known “high-risk” pathological features of cSCC 
tumours and the degree of active TGF-β family signalling. 
A consistent association and significant correlation 
between low PO4-SMAD2/3 expression and thick tumours 
(≥4mm depth) was identified. Importantly, the strength of 
this association was such that increasing tumour depth 
remained an independent predictor of low tumour PO4-
SMAD expression when accounting for all other “high-
risk” variables. This correlation provides further evidence 
that TGF-β signalling appears to be acting primarily as a 
tumour suppressor in cSCC and suggests that a reduction 
in active TGF-β signalling may provide a significant 
growth advantage for affected tumour cells - as recently 
demonstrated in-vitro using primary human cSCC cell 
lines carrying mutant TGFBR2 and lacking canonical 
signalling potential [3]. As tumour thickness represents 
a pathological marker of invasion, it also indicates that 
active canonical SMAD signalling may not preclude 
Table 3: Binary logistic regression model identifies tumour depth as an independent predictor of lower cSCC 
R-Smad activity
Variable DF Χ2 (Wald) P (<0.05) R.R 95% CI
Depth 1 7.447 0.006 1.127 1.034-1.227
Poorly diff 1 3.125 0.077
Site = Lower limb 1 1.168 0.280
Diameter - 1.107 0.293
Invasion beyond fat 1 0.739 0.390
Site = Torso 1 0.629 0.428
Clark level ≥IV 1 0.140 0.708
Site = Upper limb 1 0.114 0.736
Site = High-risk H&N 1 0.82 0.774
PNI 1 0.48 0.827
Site = Low-risk H&N 1 0.019 0.889
Binary outcome = TGF-β Signalling “off” * (0=No, 1=Yes).
*≤25th Percentile of the mean (PO4-SMAD2 = ≤ 76, PO4-SMAD3 = ≤ 41). B = Co-efficients, S.E = Standard error of 
co-efficients, Wald = Wald chi-squared value. df = degree of freedom, Sig. = 2-tailed p-value for testing null hypothesis. 
Exp(B) = Exponentiation of co-efficients (Odds ratios), C.I = Confidence intervals. H&N = Sun-exposed head and neck, 
Clark Level IV = Invasion into the reticular dermis, PNI = Perineural invasion.
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features of tumour progression, such as tumour invasion, 
in human cSCC.
Recent studies in mice suggest that HF and IFE stem 
cells are epigenetically primed differentially to undergo 
epithelial to mesenchymal transition during tumourigenesis, 
with HF derived cells more likely to acquire a canonical 
TGF-β/SMAD2-driven EMT phenotype than IFE derived 
cells [45]. Thus, the epigenetic state of the cancer cells 
of origin may have a significant impact on the outcome 
of TGF-β mediated signalling. Since EMT is reported 
to be required for SCC dissemination [46], how these 
observations relate to tumourigenic events in human skin 
warrants further investigation. This study indicates that 
reduced canonical signalling via the SMADs correlates 
with high risk phenotypic changes, however, as the TGF-β 
pathway can also activate non-SMAD pathways such as the 
Mitogen Activated Protein (MAP) kinase pathway, Rho-
like GTPase pathways (RhoA) and Phosphatidylinositol-
3-kinase (PI3K)/Protein Kinase B (AKT) pathways [47], 
it is possible that, as TGF-β’s SMAD-dependent tumour 
suppressor arm is impaired, pro-tumourigenic non-SMAD 
pathways dominate to drive invasion and metastasis [48]. 
Interestingly, the detection of EMT markers in SCC tumours 
correlates with upregulation of phosphorylated forms of 
active AKT, suggesting that signalling through AKT may be 
involved in EMT and could be targeted to suppress invasion 
[46]. It is unknown, however, whether AKT activation in 
SCC is TGF-β receptor dependent. Further analysis of the 
TMA for expression of both SMAD-dependent and non-
SMAD dependent target genes and their correlation with 
PO4-SMAD expression may shed further light on whether 
such cross-talk has a role in human cSCC tumour tissue.
Significant tumour thickness (or depth of invasion) 
is a known risk factor for nodal metastasis (NM) in human 
cSCC [49, 50]. Our findings lead to the hypothesis that 
a reduction in signalling via SMADs may also correlate 
with increased risk of NM. This was not tested directly 
as the number of patients re-presenting with NM was too 
low to justify the analysis at this current time (n=2/249; 
data not shown). Such analysis was also compounded 
by two patient factors: the first being that most patients 
presenting with cSCC were elderly (63% over 80 yrs old 
in this study) which limits possible follow-up times and 
the likelihood of disease recurrence prior to mortality 
unrelated to cSCC disease progression; and secondly, the 
fact that the majority of the patients in this study presented 
with SCC between 2012 and 2014 and, to date, the follow-
up times are too short to accumulate sufficient numbers of 
NM for analysis. There is an established link between loss 
of TGF-β signalling and the mode of tumour invasion, for 
example, murine and rat in-vivo breast carcinoma models 
reveal that blockade of TGF-β signalling drives cohesive 
(or collective) tumour cell migration and invasion [51, 52]. 
Importantly, cells invading collectively appear primed for 
lymphatic rather than blood-borne spread [51] in both 
breast cancer and HNSCC models [52, 53]. If this process 
could also be demonstrated in the context of cSCC, it 
would suggest that a reduction in active TGF-β signalling 
could prime cSCC tumour cells for collective tumour cell 
invasion and potentially drive their natural predilection for 
lymphatic spread. Given this, further investigation into the 
loss of endogenous PO4-SMAD activity as a biomarker for 
aggressive disease in cSCC is warranted.
MATERIALS AND METHODS
This study was conducted according to the Declaration 
of Helsinki Principles. Ethical approval was obtained 
from the local NHS Tayside Research Ethics Committee - 
Research Ethics Number: NHS REC 08.S1401.69 – “The 
Molecular Pathogenesis of Non-melanoma Skin Cancers”. 
All patients participating in this study provided written, 
informed consent. Normal scalp skin was only obtained 
as redundant “dog-ear” tissue following minor plastic 
surgery procedures for benign lesions. Lesional and peri-
lesional tissue from a total of 249 patients presenting to 
the Ninewells Hospital Plastic Surgery and Dermatology 
Departments, between 2007 and 2013, were included in this 
study (see Table 1 for patient/lesion details). In total, 249 
sporadic primary squamo-proliferative skin lesions from 
immunocompetent patients (one tumour per patient) were 
identified and included in the array, including: 238 primary 
invasive cSCC, 2 cSCC in-situ and 9 keratoacanthoma. 
Of these samples, 230 were represented by more than one 
independent tissue core on the TMA (92%). Of these 230 
tumours, 150 (65%) had more than one sufficient adjacent 
peri-lesional skin core for analysis.
Optimisation of immunohistochemistry (IHC) 
conditions
Primary human cSCC cell lines, SCCIC4 and 
SCCIC18 were cultured in standard conditions using RM+ 
media (10% FCS) as previously described [54]. Adherent 
sub-confluent monolayers of at least 5×106 cells in 75 
cm2 tissue culture flasks were treated with either vehicle 
control (4 mM HCl, 1 mg/mL BSA; DMSO, 1:1000 
dilution), 1 ng/mL TGF-β1 (positive sample) or 10 μM 
TGFBR1 kinase inhibitor SB-431542 (negative sample) 
[18] for 1 hour. Cells were fixed in formalin, the cell 
pellets re-suspended in agarose and then embedded in 
paraffin prior to sectioning and IHC staining as previously 
described [55].
Western blotting
Cells were lysed in SDS lysis buffer and analysed 
by SDS-polyacrylamide gel electrophoresis and western 
blotting. Bound immunocomplexes were detected by 
enhanced chemiluminescence (ECL; Amersham). All 
primary and secondary antibodies used are described in 
supplementary information.
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IHC of FFPE tissue sections
Normal skin samples were fixed immediately in 
4% paraformaldehyde and processed using a standard 
automated histology processor prior to embedding into 
paraffin wax blocks. For all IHC staining four-micron 
thick sections were cut onto Polysine-coated slides and 
air dried at room temperature prior to de-paraffinisation 
and rehydration via a graded alcohol series. Citrate 
buffer antigen retrieval and DAKO autostaining (Ely, 
Cambridgeshire, UK) using Vectastain® ABC kits 
(Vector Labs, Burlingame, CA, USA) was performed 
as per manufacturer’s instructions and as described in 
supplementary methods. The antibodies used for IHC are 
described in supplementary methods.
Tissue microarray (TMA)
Lesions were identified by the retrospective 
collection of pathology reports containing minimum 
datasets for primary cSCC [56]. H&E slides were then 
reviewed, marked and used as templates for coring from 
their corresponding paraffin blocks using a manual tissue 
arrayer. A maximum of six x 1mm cores at least 3mm 
thick per specimen were targeted for inclusion. Cores 
were constructed in a grid design, facilitated by TMA 
DesignerR2 software. Matched lesional and peri-lesional 
samples were arranged in random order.
Image processing and digital image analysis
All stained sections were scanned using the Aperio® 
Scanscope XT slide scanner (Aperio® Technologies, Inc., 
Vista, CA) and visualised digitally online using the Aperio 
e-slide manager via the Tayside Tissue Bank: https://
aperio-sql.tissuebank.dundee.ac.uk/.
Quantification of immunostaining and statistical 
analyses
All tissue sections were scored for protein expression 
levels via a simplified Histoscore method [19] as described 
in Supplementary methods. To account for heterogeneity 
of staining between tumour and stroma, only positive 
tumour cells and skin keratinocytes were scored. Scoring 
was undertaken remotely by four trained independent 
investigators blinded to the TMA structure and original 
pathology reports. Statistical analysis included paired 
samples T-test (Sig. p<0.05), non-parametric correlations 
between staining intensities and clinic-pathological variables 
(Spearmans-Rho - Sig. p<0.05) and binary logistic regression. 
All statistics were performed using SPSS v20 (IBM).
Abbreviations
cSCC, cutaneous squamous cell carcinoma. IHC, 
immunohistochemistry. FFPE, formalin-fixed paraffin 
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like kinase.
Author contributions
Participated in research design: Rose, Proby, Leigh, 
Inman
Conducted experiments: Rose, Bray, Coates, Dayal, 
Purdie.
Performed data/TMA analysis: Rose, Bray 
(constructed), Mitchell, Stephens, Rickaby, Evans, Inman
Wrote or contributed to the writing of the 
manuscript: Rose, Spender, Proby and Inman.
ACKNOWLEDGMENTS
We thank all patients who generously donated 
tissue to the Tayside Biorepository, Dundee for 
research. We acknowledge staff at the Department of 
Pathology, Ninewells Hospital, the Chief Scientist 
Office, NHS Scotland and the Tayside Biorepository, 
Dundee. We would particularly like to acknowledge 
and thank the Tayside Biorepository staff for their 
contributions to acquiring paraffin embedded and 
fresh tissue samples, in particular Sally Chalmers 
(S.C) and Kate McLean (K.McL) for contributions to 
patient consent, tissue acquisition and storage (S.C) 
and construction of the tissue microarray (K.McL and 
S.B). Additionally, we would like to thank Dr Simon 
A Ogston, Lecturer in Medical Statistics, School 
of Medicine, University of Dundee, for counsel on 
statistical data analysis.
CONFLICTS OF INTEREST
We declare no conflicts of interest.
FUNDING
A.M.R. was supported by Cancer Research UK 
[Clinical PhD Fellowship/Centre grant (A12976) and 
Postdoctoral Research Bursary for Clinical Trainees 
(A22912)] and the Academy of Medical Sciences [Starter 
Grant for Clinical Lecturers (SGL015\1022)]. G.J.I., K.J.P, 
C.A.H, I.M.L. and C.M.P. were supported by a Cancer 
Research UK programme grant (A13044) and a European 
Research Council grant (250170). L.C.S. was supported 
by Worldwide Cancer Research grant (11-0788).
REFERENCES
1. Stern RS. Prevalence of a history of skin cancer in 2007: 
results of an incidence-based model. Arch Dermatol. 2010; 
146:279–282.
Oncotarget14564www.impactjournals.com/oncotarget
2. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy 
GF, Qureshi AA, Schmults CD. Evaluation of american 
joint committee on cancer, international union against 
cancer, and brigham and women's hospital tumor staging 
for cutaneous squamous cell carcinoma. J Clin Oncol. 2014; 
32:327–34.
3. Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, 
Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh 
A, Pourreyron C, Dayal JHS, Larsson J, et al. Inactivation 
of TGFβ receptors in stem cells drives cutaneous squamous 
cell carcinoma. Nature communications. 2016; 7:12493.
4. Shi Y, Massague J. Mechanisms of tgf-beta signaling from 
cell membrane to the nucleus. Cell. 2003; 113:685–700.
5. Massague J. Tgfbeta in cancer. Cell. 2008; 134:215–230.
6. Inman GJ. Switching TGFbeta from a tumor suppressor to 
a tumor promoter. Curr Opin Genet Dev. 2011; 21:93–99.
7. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain 
A, Akhurst RJ. TGFbeta1 inhibits the formation of benign 
skin tumors, but enhances progression to invasive spindle 
carcinomas in transgenic mice. Cell. 1996; 86:531–542.
8. Perez-Lorenzo R, Markell LM, Hogan KA, Yuspa SH, Glick 
AB. Transforming growth factor beta1 enhances tumor 
promotion in mouse skin carcinogenesis. Carcinogenesis. 
2010; 31:1116–1123.
9. Han G, Lu SL, Li AG, He W, Corless CL, Kulesz-Martin 
M, Wang XJ. Distinct mechanisms of tgf-beta1-mediated 
epithelial-to-mesenchymal transition and metastasis during 
skin carcinogenesis. J Clin Invest. 2005; 115:1714–1723.
10. Hoot KE, Lighthall J, Han G, Lu SL, Li A, Ju W, Kulesz-
Martin M, Bottinger E, Wang XJ. Keratinocyte-specific 
Smad2 ablation results in increased epithelial-mesenchymal 
transition during skin cancer formation and progression. J 
Clin Invest. 2008; 118:2722–32.
11. Harradine KA, Ridd K, Saunier EF, Clermont FF, Perez-
Losada J, Moore DH, Epstein EH Jr, Bastian BC, Akhurst 
RJ. Elevated cutaneous smad activation associates with 
enhanced skin tumor susceptibility in organ transplant 
recipients. Clin Cancer Res. 2009; 15:5101–5107.
12. Wrana JL, Attisano L, Wieser R, Ventura F, Massague 
J. Mechanism of activation of the TGF-[beta] receptor. 
Nature. 1994; 370:341–347.
13. Wieser R, Wrana JL, Massagué J. GS domain mutations that 
constitutively activate T beta R-I, the downstream signaling 
component in the TGF-beta receptor complex. The EMBO 
Journal. 1995; 14:2199–2208.
14. Wu JW, Hu M, Chai J, Seoane J, Huse M, Li C, Rigotti 
DJ, Kyin S, Muir TW, Fairman R, Massagué J, Shi Y. 
Crystal structure of a phosphorylated Smad2. Recognition 
of phosphoserine by the MH2 domain and insights on Smad 
function in TGF-β signaling. Mol Cell. 2001; 8:1277–89.
15. Xu L, Chen YG, Massague J. The nuclear import function 
of smad2 is masked by SARA and unmasked by TGFbeta-
dependent phosphorylation. Nat Cell Biol. 2000; 2:559–562.
16. Massague J. TGF[beta] signalling in context. Nat Rev Mol 
Cell Biol. 2012; 13:616–630.
17. South AP, Purdie KJ, Watt SA, Haldenby S, den Breems 
NY, Dimon M, Arron ST, Kluk MJ, Aster JC, McHugh A, 
Xue DJ, Dayal JH, Robinson KS, et al. NOTCH1 mutations 
occur early during cutaneous squamous cell carcinogenesis. 
J Invest Dermatol. 2014; 134:2630–2638.
18. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster 
LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent 
and specific inhibitor of transforming growth factor-beta 
superfamily type i activin receptor-like kinase (ALK) 
receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002; 
62:65–74.
19. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller 
P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, 
Coates PJ, Vojtesek B. Discriminating functional and 
non-functional p53 in human tumours by p53 and MDM2 
immunohistochemistry. J Pathol. 2005; 207:251–259.
20. Mesa KR, Rompolas P, Greco V. The Dynamic Duo: Niche/
Stem Cell Interdependency. Stem Cell Reports. 2015; 
4:961–966.
21. Purba TS, Haslam IS, Poblet E, Jimenez F, Gandarillas A, 
Izeta A, Paus R. Human epithelial hair follicle stem cells 
and their progeny: current state of knowledge, the widening 
gap in translational research and future challenges. 
Bioessays. 2014; 36:513–525.
22. Ito M, Kizawa K, Hamada K, Cotsarelis G. Hair follicle 
stem cells in the lower bulge form the secondary germ, 
a biochemically distinct but functionally equivalent 
progenitor cell population, at the termination of catagen. 
Differentiation. 2004; 72:548–557.
23. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy 
GF, Qureshi AA, Schmults CD. Evaluation of American 
Joint Committee on Cancer, International Union Against 
Cancer, and Brigham and Women's Hospital tumor staging 
for cutaneous squamous cell carcinoma. J Clin Oncol. 2014; 
32:327–334.
24. Quan T, He T, Kang S, Voorhees JJ, Fisher GJ. Ultraviolet 
irradiation alters transforming growth factor beta/smad 
pathway in human skin in vivo. J Invest Dermatol. 2002; 
119:499–506.
25. Wang XJ, Liefer KM, Tsai S, O'Malley BW, Roop DR. 
Development of gene-switch transgenic mice that inducibly 
express transforming growth factor beta1 in the epidermis. 
Proc Natl Acad Sci USA. 1999; 96:8483–8488.
26. Liu X, Alexander V, Vijayachandra K, Bhogte E, Diamond 
I, Glick A. Conditional epidermal expression of TGFbeta 
1 blocks neonatal lethality but causes a reversible 
hyperplasia and alopecia. Proc Natl Acad Sci USA. 2001; 
98:9139–9144.
27. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer 
TA. Latent Tgf-[bgr] structure and activation. Nature. 2011; 
474:343–349.
Oncotarget14565www.impactjournals.com/oncotarget
28. Vizan P, Miller DS, Gori I, Das D, Schmierer B, Hill 
CS. Controlling long-term signaling: receptor dynamics 
determine attenuation and refractory behavior of the TGF-
beta pathway. Sci Signal. 2013; 6:ra106.
29. Xie W, Bharathy S, Kim D, Haffty BG, Rimm DL, Reiss 
M. Frequent alterations of smad signaling in human head 
and neck squamous cell carcinomas: a tissue microarray 
analysis. Oncol Res. 2003; 14:61–73.
30. Schmierer B, Hill CS. Tgfbeta-smad signal transduction: 
molecular specificity and functional flexibility. Nat Rev 
Mol Cell Biol. 2007; 8:970–982.
31. Hinck AP. Structural studies of the TGF-βs and their 
receptors – insights into evolution of the TGF-β 
superfamily. FEBS Letters. 2012; 586:1860–1870.
32. McDowall M, Edwards NM, Jahoda CAB, Hynd PI. The 
role of activins and follistatins in skin and hair follicle 
development and function. Cytokine & Growth Factor 
Reviews. 2008; 19:415–426.
33. Hubner G, Hu Q, Smola H, Werner S. Strong induction of 
activin expression after injury suggests an important role 
of activin in wound repair. Dev Biol. 1996; 173:490–498.
34. Shimizu A, Kato M, Nakao A, Imamura T, ten Dijke 
P, Heldin CH, Kawabata M, Shimada S, Miyazono K. 
Identification of receptors and smad proteins involved in 
activin signalling in a human epidermal keratinocyte cell 
line. Genes Cells. 1998; 3:125–134.
35. Lange D, Persson U, Wollina U, ten Dijke P, Castelli E, 
Heldin CH, Funa K. Expression of tgf-beta related smad 
proteins in human epithelial skin tumors. Int J Oncol. 1999; 
14:1049–1056.
36. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: 
differential roles and regulation of smad2 and smad3 in 
TGF-β signaling. J Cell Biochem. 2007; 101:9–33.
37. Tsuji Y, Denda S, Soma T, Raftery L, Momoi T, Hibino T. A 
potential suppressor of tgf-[beta] delays catagen progression 
in hair follicles. J Investig Dermatol Symp Proc. 2003; 
8:65–68.
38. Foitzik K, Lindner G, Mueller-Roever S, Maurer M, 
Botchkareva N, Botchkarev V, Handjiski B, Metz M, 
Hibino T, Soma T, Dotto GP, Paus R. Control of murine hair 
follicle regression (catagen) by TGF-beta1 in vivo. FASEB 
J. 2000; 14:752–760.
39. Oshimori N, Fuchs E. Paracrine tgf-beta signaling 
counterbalances bmp-mediated repression in hair follicle 
stem cell activation. Cell stem cell. 2012; 10:63–75.
40. Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, 
Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, 
Muzny DM, Doddapaneni H, et al. Mutational landscape of 
aggressive cutaneous squamous cell carcinoma. Clin Cancer 
Res. 2014; 20:6582–6592.
41. Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, 
Hammerman PS. Genomic analysis of metastatic cutaneous 
squamous cell carcinoma. Clin Cancer Res. 2015; 
21:1447–1456.
42. Goudie DR, D'Alessandro M, Merriman B, Lee H, 
Szeverenyi I, Avery S, O'Connor BD, Nelson SF, Coats SE, 
Stewart A, Christie L, Pichert G, Friedel J, et al. Multiple 
self-healing squamous epithelioma is caused by a disease-
specific spectrum of mutations in TGFBR1. Nat Genet. 
2011; 43:365–369.
43. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler 
J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, 
Andre J, Kamsu-Kom N, Boussemart L, et al. Skin tumors 
induced by sorafenib; paradoxic RAS-RAF pathway 
activation and oncogenic mutations of hras, TP53, and 
TGFBr1. Clin Cancer Res. 2012; 18:263–272.
44. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, 
Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP. Phase i 
study of gc1008 (fresolimumab): a human anti-transforming 
growth factor-beta (TGFβ) monoclonal antibody in patients 
with advanced malignant melanoma or renal cell carcinoma. 
PLoS ONE. 2014; 9:e90353.
45. Latil M, Nassar D, Beck B, Boumahdi S, Wang L, 
Brisebarre A, Dubois C, Nkusi E, Lenglez S, Checinska 
A, Vercauteren Drubbel A, Devos M, Declercq W, et al. 
Cell-type-specific chromatin states differentially prime 
squamous cell carcinoma tumor-initiating cells for epithelial 
to mesenchymal transition. Cell stem cell. 2017; 20:191–
204 e195.
46. Barrette K, Van Kelst S, Wouters J, Marasigan V, Fieuws 
S, Agostinis P, van den Oord J, Garmyn M. Epithelial-
mesenchymal transition during invasion of cutaneous 
squamous cell carcinoma is paralleled by AKT activation. 
The British journal of dermatology. 2014; 171:1014–1021.
47. Derynck R, Muthusamy BP, Saeteurn KY. Signaling 
pathway cooperation in tgf-beta-induced epithelial-
mesenchymal transition. Curr Opin Cell Biol. 2014; 
31:56–66.
48. Davies M, Prime SS, Eveson JW, Price N, Ganapathy A, 
D’Mello A, Paterson IC. Transforming growth factor-β 
enhances invasion and metastasis in Ras-transfected human 
malignant epidermal keratinocytes. Int J Exp Pathol. 2012; 
93:148–156.
49. Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-
Caroli J, Rocken M, Breuninger H. Analysis of risk factors 
determining prognosis of cutaneous squamous-cell carcinoma: 
a prospective study. Lancet Oncol. 2008; 9:713–720.
50. Breuninger H, Brantsch K, Eigentler T, Hafner HM. 
Comparison and evaluation of the current staging of cutaneous 
carcinomas. J Dtsch Dermatol Ges. 2012; 10:579–586.
51. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai 
E. Localised and reversible TGFβ signalling switches breast 
cancer cells from cohesive to single cell motility. Nature 
cell biology. 2009; 11:1287–1296.
52. Matise LA, Palmer TD, Ashby WJ, Nashabi A, Chytil A, 
Aakre M, Pickup MW, Gorska AE, Zijlstra A, Moses HL. 
Lack of transforming growth factor-beta signaling promotes 
collective cancer cell invasion through tumor-stromal 
crosstalk. Breast Cancer Res. 2012; 14:R98.
Oncotarget14566www.impactjournals.com/oncotarget
53. Le Bras GF, Taylor C, Koumangoye RB, Revetta 
F, Loomans HA, Andl CD. TGFbeta loss activates 
ADAMTS-1-mediated EGF-dependent invasion in a 
model of esophageal cell invasion. Exp Cell Res. 2015; 
330:29–42.
54. Proby CM, Purdie KJ, Sexton CJ, Purkis P, Navsaria 
HA, Stables JN, Leigh IM. Spontaneous keratinocyte cell 
lines representing early and advanced stages of malignant 
transformation of the epidermis. Exp Dermatol. 2000; 
9:104–117.
55. Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, 
O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, 
Thurlow JK, Lattanzio L, Monteverde M, et al. Epigenetic 
downregulation of human disabled homolog 2 switches 
TGF-beta from a tumor suppressor to a tumor promoter. J 
Clin Invest. 2010; 120:2842–2857.
56. Slater D, Walsh M. Dataset for the histological reporting of 
primary invasive cutaneous squamous cell carcinoma and 
regional lymph nodes. The Royal College of Pathologists. 
2014.
